Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramucirumab + paclitaxel + docetaxel + irinotecan
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ramucirumab is a fully human monoclonal antibody that targets and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby blocking the binding of VEGF ligands and inhibiting angiogenesis, which is critical for tumor growth and metastasis. Paclitaxel and docetaxel are taxane-class small molecule chemotherapeutic agents that stabilize microtubules, preventing cell division. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication in cancer cells. These drugs are used in various combinations for the treatment of advanced or metastatic cancers, particularly gastric/gastroesophageal junction cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Ramucirumab is developed by Eli Lilly and marketed under the brand name Cyramza[5][6][7]. Paclitaxel (Taxol) was originally developed by Bristol Myers Squibb; docetaxel (Jevtana) by Sanofi; irinotecan (Camptosar) by Pfizer.
- Brand names
- Jevtana
- Other names
- ramucirumab + paclitaxel + docetaxel + irinotecan
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)MicrotubuleTOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on ramucirumab + paclitaxel + docetaxel + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramucirumab + paclitaxel + docetaxel + irinotecan.